. Author manuscript; available in PMC: 2015 Dec 30.

Published in final edited form as: Ann Hematol. 2015 Jul 31;94(11):1875–1883. doi: 10.1007/s00277-015-2462-4

Table 2.

Cross-correlations between NLR, high-dose chemotherapy followed by ASCT, age, cytogenetics, single-novel agent use and ISS stage

Factor	ISS I	ISS II	ISS III	p value
NLR ≥2	44/95 (46 %)	48/106 (45 %)	51/108 (47 %)	0.96
High-dose therapy followed by ASCT	44/95 (46 %)	43/106 (41 %)	26/108 (24 %)	0.0007
Age >65 years	30/95 (32 %)	43/106 (41 %)	65/108 (60 %)	0.0003
Adverse cytogenetics	12/51 (24 %)	7/53 (13 %)	10/62 (16 %)	0.1
Single novel agent	68/95 (72 %)	88/106 (83 %)	92/108 (85 %)	0.04

ISS international staging system, ASCT autologous stem cell transplantation